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1. Introduction 
Chronic renal injury can be mediated by angiotensin II (Ang II) through hemodynamic and 
inflammatory mechanisms and attenuated by individual suppression of these mediators. 
Hypertension is usually associated with the development of vascular and renal fibrosis [3]. 
This pathophysiological process is characterized by structural changes in vasculature caused 
by increased synthesis and rearrangement of extracellular matrix proteins, such as the 
collagen type I [4]. Several studies support a major role for the renin-angiotensin system in 
the development of fibrosis [5, 6]. 
Hypertension injures blood vessels and thereby causes end-organ damage. The mechanisms 
are complicated and although they have been studied for decades in experimental animal 
models [7], they are only currently being elucidated. From the efforts of many investigators, 
we are now in the position of constructing a chain of events from the endothelium to the 
underlying matrix, to the vascular smooth muscle cells, and beyond to the adventitia, and 
surrounding tissues. The endothelial layer acts as a signal transduction interface for 
hemodynamic forces in the regulation of vascular tone and chronic structural remodeling of 
arteries [8]. Infiltration of the permeabilized endothelium by leukocytes sets the stage for an 
inflammatory cascade, involving cytokines, chemokines, growth factors, and matrix 
metalloproteinases. Altered integrin signaling, the production of tenacin, epidermal growth 
factor signaling, tyrosine phosphorylation, and activation of downstream pathways 
culminate in vascular smooth muscle cell proliferation [9]. Evidence is accumulating that 
matrix molecules provide an environment which decreases the rate of programmed cell 
death [10]. 
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Hypertension is a major risk factor for renal and cardiac damage, however, the mechanisms 
are incompletely understood. Angiotensin (Ang) II, the key effector of the local and 
circulating renin-angiotensin system (RAS), plays a central role [11-12]. In addition to its 
vasoactive and growth-promoting action, Ang II stimulates circulating leukocytes and 
endothelial cells, thereby promoting inflammation and interstitial extracellular matrix 
accumulation [13-17]. Many inflammation-mediating genes are activated by the 
transcription nuclear factor-B (NF-B), which resides inactive and bound to the inhibitory 
protein I-B in the cytoplasm of T lymphocytes, monocytes, macrophages, endothelial cells, 
and smooth muscle cells [18-19]. Ang II stimulates NADPH oxidase, which generates 
reactive oxygen species (ROS) [20]. ROS may act as signal transduction messengers for 
several important transcription factors, including NF-B and AP-1 (activator protein-1) [21]. 
Recently, Ozes et al [22]showed that Akt/protein kinase B (Akt) is essential in tumor 
necrosis factor- (TNF-)–induced activation of NF-B. Takahashi et al, [23] as well as 
Ushio-Fukai et al, [24] have demonstrated Akt activation by Ang II, which may involve 
ROS. Akt-induced activation of NF-kB upregulates numerous genes, including interleukin 
(IL)-1, IL-6, IL-8, interferon-, TNF-, intercellular adhesion molecule-1 (ICAM-1), vascular 
cell adhesion molecule-1 (VCAM-1), and the chemokine MCP-1 (monocyte chemoattractant 
protein-1). Several reports [25-27] indicated that angiotensin converting enzyme (ACE) 
inhibition decreased NF-B in renal disease. 
We have previously demonstrated that traditional Chinese medicine prescription 
documented in the ancient Chinese pharmacopoeia or monographs promoted blood 
circulation, decreased blood stasis, and improved renal function. They decreased urinary 
protein excretion ,balanced lipid metabolism and enhanced the effects of antioxidant in the 
treatment of patients with early and middle stage chronic renal failure [28-32].  
It has been showen broad foreground to postpone progression of chronic renal dysfunction. 
But it is unclear that effective composition and mechanism of renal protection. Therefore, 
the study presented here was designed to test the hypothesis that HE-86 liquid extract, 
which is effective unite refined from above Chinese prescription, would prevent chronic 
renal failure rats induced by nephrectomized, in association with decreased expression of 
angiotensin II and AT- II receptors, further to suppress high expression of inflammatory and 
growth factors. In an attempt to obtain more effective renal protection, research design 
consisted of a group of Nx rats receiving a HE-86 liquid extract treatment comparing with 
chronic renal failure rats induced by subtotal nephretomized without treatment. At same 
time, in the present study, we also assess the influence of renal mass reduction (RMR) 
caused by subtotal (5/6) nephrectomy on gene expression for NF-B, TNF- and TGF-beta1 
and evaluate the correlation between expression of these genes and activity of the intrarenal 
renin-angiotensin systems. The research result showed HE-86 played a critical role in 
improving renal disease and was a key mediator in delay process of vascular fibrosis, 
characterized by reduced lumen diameter and arterial wall thickening attributable to 
excessive deposition of extracellular matrix (ECM) through by the model study. 
2. Materials and methods 
2.1 Experimental design 
Thirty-six of the normal kidney mass were removed from adult male Munich-Wistar rats 
(BiKai, Shanghai, China) weighing 200–210 g to make animal models of CRF. In a first  
www.intechopen.com
Molecular Mechanisms of Nephro-Protective  
Action of HE-86 Liquid Extract in Experimental Chronic Renal Failure 
 
177 
session, two thirds of the left kidney were removed. One week after the first operation, the 
right kidney was removed. These procedures were performed under anaesthesia with 
sodium pentobarbital (The ShuGuang pharmaceutical factory in Shanghai). Two weeks after 
5/6-nephrectomy, 24 rats were divided into pairs such that both rats in each pair exhibited 
almost the same levels of serum creatinine, blood urea nitrogen (BUN) (Table 1). One rat 
from each pair was assigned to (i) control uraemic group (n=12), the other to (ii) treatment 
uraemic group (n=12) which received HE-86, extract liquid which is effective composition 
isolated from Chinese medicine prescription, everyday at a dose of 0.75 g/100 g body 
weight for 8 weeks. For normal controls, rats underwent a sham operation consisting of 
laparotomy and manipulation of the renal pedicles but without damage to the kidney(n=12). 
The treatment group were administered by HE-86 infuse the stomach as pair-fed with the 
control uraemic rats, and the normal rats were fed ad libitum with standard solid chow 
(BiKai Animal Lab. Company, Shanghai, China) containing 24.5% protein.  
 
 N BUN(mmol/L) Scr(μmol/L)  
sham 12 7.510.75 19.004.00 
control 12 16.170.99* 49.506.53* 
treatment 12 16.182.42* 49.239.36* 
 
Table 1. The variation of serum creatinine and blood urea nitrogen before treatment.  
Blood pressure was measured before treatment and every two weeks after surgery. The 
levels of serum creatinine (Scr), Blood urea nitrogen (BUN), 24h urine protein excreation 
and urine TGF–ǃ were determined at 4 or 8 weeks after starting the administration of HE-86, 
respectively. The remnant kidneys were removed after perfusion at the end of experiment 
for histopathological and gene expression studies.  
2.2 Analytical procedures 
Renal Function Assessment and Blood Pressure Measurement  
Serum creatinine (Scr) and Blood urea nitrogen (BUN) were measured using a Beckman Cx4 
analyser (Fullerton, CA, USA), respectively. 
24h Urinary protein concentrations were determined by the Bradford method, adapted to a 
microtiter plate assay. Coomassie reagent (USB, Cleveland, OH) was added to the diluted 
urine samples. After 10 minutes, the absorbance at 595-nm wavelength was read on ELX800 
microplate reader (Bio-Tek Instruments, VT). The protein concentrations were calculated by 
reference to bovine serum albumin (Sigma) standards.  
Systolic blood pressure was recorded by tail plethysmography using the BP2000 blood 
pressure analysis system (Visitech Systems, Inc., Apex, NC) in conscious rats at baseline and 
every 2 weeks throughout the experimental time course. 
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2.3 Immunohistochemical analysis 
Immunostaining of NF-κb (Sigma) in renal tissue sections was performed using the 
streptavidin–biotinylated peroxidase complex (SABC) method. The tissue specimens were 
divided into thin sections (4-µm thick) that were then deparaffinized. The sections were 
washed three times with distilled water for 5 min. The sections were treated with Protease K 
(Try box produced by BSD living creature technique company of Wuhan) in distilled water 
at 37°C for 15 min, and washed three times with PBS for 10 min. Endogenous peroxidase 
activity was blocked by incubating the sections with 0.3% H2O2 in methanol for 20 min at 
room temperature. The sections were washed three times with PBS for 5 min. The sections 
were incubated with 10% rabbit serum at 37°C for 60 min to reduce the non-specific 
background staining, and washed three times with PBS for 5 min. Then, the sections were 
incubated with a monoclonal anti- NF-κb antibody (7 µg/ml) dissolved in PBS containing 
3% BSA and 0.1% NaN3 at 4°C overnight, and washed three times with PBS for 10 min; 
followed by incubation with a biotinylated rabbit antibody against mouse IgG+IgA+IgM (10 
µg/ml) at 37°C for 40 min. The sections were washed three times with PBS for 5 min, and 
then incubated with peroxidase-labelled streptavidin at 37°C for 30 min. After washing 
three times with PBS for 10 min, the reaction was completed by the addition of 
diaminobenzidine–H2O2 solution for 15 min, and washed three times with distilled water 
for 5 min, then the slides were counter-stained with methylgreen.  
The primary anti- NF-κb antibody (1 : 100) was incubated with NF-κb (10 mg/ml) at 4°C 
overnight. After centrifuging the mixture at 10,000xg for 30 min, the supernatant was used 
as negative control for the primary antibody solution followed by the usual SABC method. 
There was no positive staining in the renal cortex when the primary antibody was pre-
incubated with NF-κb. 
The immunostaining of NF-κb was quantified using an image analyser IMS (FUDAN 
university of medical science portrait examination center) by evaluating the positively 
stained area of the sections under the same light intensity for microscopy. The intensity of 
colour component for red, green or blue was graded from 0 to 256°. Areas which showed 
intense brown color were extracted from the microscopic fields (number of fields for each 
tissue sample, six fields; magnification on the display: x300) under the following conditions; 
red component ranging from 104 to 158°, green component from 81 to 129°, and blue 
component from 70 to 123°.  
3. Real-time quantitative Polymerase Chain Reaction (PCR) for TNF－α, Ang II 
and AT1R 
To investigate the expression of TNF–ǂ mRNA, Ang II and AT1R real-time PCR (BC living 
creature technique company, Shanghai, China) was performed with the Opticon real-time 
PCR machine (FX scientific research Inc. Shanghai, China). Briefly, total RNA was extracted 
from renal tissues. All of the RNA samples were treated with the RNase-free DNase I 
(GIBCO BRC Inc, Shanghai, China) before the RT-PCR. Real-time quantitative one-step RT-
PCR assay was performed to quantify mRNA using real-time PCR machine (FX scientific 
research Inc. Shanghai, China). The primers used for real-time RT-PCR were as follows: 
TNF-a: forward 5’-CTCATTCCCGCTCGTGG-3’ reverse 3’-CGTTTGGTGGTTCGTCTCC- 5’; 
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AT1R: forward 5’-CTTGTTCCCTTTCCTTATC -3’reverse 3’-ACTCCACCTCACTGTCCA - 
5’. Ang II : forward 5'- ACCTG CATGA GTGTT GATAGG-3' reverse 3'-ACTTCA ATATC 
GTCAGT AACTGGAC-5'. 
Total RNA of osteoblasts was isolated by using TRIzol reagent (Invitrogen) and reverse 
transcription was performed follow manufacturer’s manual(BioTNT, Shanghai, China). 
Quantitative real-time PCR, enabling the quantification of relative gene expression, was 
performed using SYBR green DNA binding fluorescent dye. 10 μL of QuantiTect TM 
SYBR Green PCR Master Mix, 4 μL of QuantiTect TM SYBR Green primer assay 
(osteocalcin, b-actin; all provided by BioTNT), 5 μL of RNase free water and 1 μL of cDNA 
(1 ng/μL) were used for one reaction. Quantitative real-time PCR was performed in 
triplicates with the following cycler program: 95°C 10 min, denaturation step: 95°C 15 s, 
annealing step: 60°C 15 s, elongation step: 72°C 30 s; dissociation: 95°C 15 s, 60°C 1min, 
95°C 15 s, 40 cycles were performed in total. B-actin was taken as an endogenous standard 
and relative gene expression was determined using the ΔΔCt method. Gene expression 
was compared by setting control cultures to 1 (reference value) as indicated in the 
relevant figures. 
Quantitative analyses of TNF, ǂ, Ang II and AT1R expression were performed using a 
quantitative image analysis system (FR-2000,FR Science and technology Inc, Shanghai 
China). Because the pattern of expression of TNFǂ, Ang II and AT1R are diffuse in nature, 
the percentage of positive staining in the renal tissue was quantified under a ×20 power 
field of microscope. Briefly, up to 10 random areas of kidney with the early stage 
(media:intima ≥1) and advanced stage (media:intima <1) were chosen from each tissue 
section and examined. The examined area was outlined, the positive staining patterns were 
identified, and the percent positive area in the examined area was then measured. Data were 
expressed as the percentage of mean±SEM. 
4. Characterization of monoclonal anti-TGF–β antibody 
The reactivity of the produced monoclonal antibodies with Urine TGF–ǃ was screened by 
enzyme-linked immunosorbent assay (ELISA) using kit produced by Section living creature 
technique limited company of Hangzhou, China (NO,13409007) The sample solution (40 µl) 
was incubated with the monoclonal anti- TGF–ǃ antibody (40 µl) at room temperature for 1 
h in an TGF–ǃ–transferrin attached microplate. After washing with phosphate-buffered 
saline (PBS) containing 0.05% Tween 20, 0.1 ml of peroxidase-labelled goat F(ab')2 fragment 
to mouse IgG(Fc) was added into the microplate, followed by incubation at room 
temperature for 1 h. After washing with PBS containing 0.05% Tween 20, 0.2 ml of o-
phenylenediamine hydrochloride (1 mg/ml) containing 0.0124% H2O2 was added to the 
microplate, and then incubated at room temperature for 30 min. The reaction was 
terminated with 1.3 M H2SO4. The absorption at 492 nm was measured.  
4.1 Statistical analysis 
Data obtained from this study are expressed as the means ± SEM. Statistical analyses were 
performed using GraphPad Prism 3.0 (GraphPad Software, Inc., San Diego, CA). Differences 
in blood pressure, serum creatinine, blood urea nitrogen, 24h urine protein and Urine TGF–
ǃ at different time points (weeks 0 to 8) within the groups, and differences of Ang II and 
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AT1R activation, TNF–ǂ expression and NF-κb accumulation in sham, control and HE86-
treated animals were assessed by one-way analysis of variance, followed by t-test. Results 
were considered statistically significant when the P value was <0.05. 
5. Result 
Renal and systemic parameters obtained at 0 (before treatment), 32and 64 days after Nx are 
given in Table 1-5, Figure 1-5. Nx groups exhibited limited growth compared with Sham. In 
all Nx groups except treatment group, body weights were statistically different from those 
observed before treatment. Average food intake was similar among groups. 
6. Effects of HE-86 administration on biochemical parameters in uraemic rats 
Table2-3 shows the summary of renal function and 24h urine protein level. There was 
significant change in body weight between the control uraemic (control) and HE-86 treated 
uraemic (treatment) rats, although they were pair-fed. body weight of treatment group was 
showed more than control uraemic. Even 4 weeks after 5/6-nephrectomy, the levels of 
serum creatinine and BUN were markedly increased as compared to sham rats. Not only at 
4 week but also at 8 week, the uraemic rats treated with HE-86 were manifested significantly 
decreased levels of serum creatinine, BUN, respectively. Urinary protein excreation was also 
suppressed obviously at 8 week as comparing with control uraemic rats.  
 N BUN(mmol/L) Scr(μmol/L)  
sham 12 6.790.70 26.251.04 
control 12 12.093.37 50.5615.83 
treatment 12 9.812.93 38.8312.00# 
Table 2. Serum creatinine and blood urea nitrogen after 4 week treatment. #P<0.05, 
##P<0.01,when compared against empty vector-treated controls 
 N BUN(mmol/L) Scr(μmol/L)  24h urine protein(mg) 
sham 12 9.31±1.05 18.88±1.55 22.34±4.4 
control 12 14.85±2.83 53.38±12.05 41.47±8.07 
treatment 12 13.62±2.81 41.00±10.51## 29.14±5.68## 
Table 3. Serum creatinine, blood urea nitrogen and twenty-four-hour urinary protein 
excretion after 8 week treatment. #P<0.05, ##P<0.01,when compared against empty vector-
treated controls 
7. Effects of HE-86 administration on mean arterial blood pressure in uraemic 
rats 
After subtotal nephrectomy, hypertension developed in both HE-86 treatment and control 
uremic rats. Blood pressure was significantly elevated from second to eighth week after 
nephrectomy compared to sham-operated animals (P < 0.05-0.01), and the rise in blood 
pressure was equivalent (systolic blood pressure 180 to 200 mmHg) in control group. After 
using HE-86 liquid extract, hypertension was obviously suppressed in treatment group, 
showing average systolic blood pressure 140 to 160 mmHg (Table 4). 
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 Before 
treatment 
After treatment 
Second week Forth week Sixth week Eighth week 
sham 137.3114.72 139.1314.06 125.507.15 150.5613.97 129.6329.16 
control 140.5023.55* 212.4643.26 199.9223.55 156.3320.72 202.4415.09 
treatment 141.7726.45* 148.5038.82＃＃ 152.4629.54＃＃ 141.0014.73＃ 176.0030.70＃ 
Table 4. Systolic blood pressure. Data represent the means ± SEM for groups of twelve rats 
treated with either HE-86 or empty vector (#P<0.05,##P<0.01,when compared against empty 
vector-treated controls;*P<0.05,**P<0.01, when compared to normal sham-controls). 
8. Effects of HE-86 administration on urine TGF－β1 
High excreation of urine TGF－ǃ1, which express both glomerular and tubulointerstitial 
injuries. To demonstrate further the anti-inflammatory effect of HE-86 on rat chronic renal 
failure, we determined the TGF－ǃ1 levels within the urine by ELISA. Results demonstrated 
that compared with vehicle, He-86 treatment significantly reduced urinary TGF－ǃ1 levels, 
corrected by decrease level of serum creatinine, throughout the entire disease course (P<0.05), 
indicating that HE-86 treatment may primarily suppress the local immune and inflammatory 
response within the diseased kidney. In contrast, overexpression of urine TGF－ǃ1 was found 
in control uraemic rats as compared with normal rats (Table 5). The experimental result 
showed the administration of HE-86 significantly inversed high expression of urine TGF－ǃ in 
uraemic rats, manifesting HE-86 to attenuate the development of glomerular sclerosis. 
 N Urine TGF－ǃ(ug/L) 
sham 12 1.830.64 
control 12 1.900.56* 
treatment 12 1.770.43# 
Table 5. Effect of HE-86 liquid extract on  urine TGF－ǃ excretion in 5/6 nephrectomy in 
rats. (#P<0.05, ##P<0.01,when compared against empty vector-treated controls; *P<0.05, 
**P<0.01, when compared to normal sham-controls) 
9. Effects of HE-86 administration on localization of NF–κB in renal tissue 
Immunohistochemical analysis was performed to determine the localization of NF–κB in the 
renal cortex (Fig.1-2). NF-B, a critical transcriptional factor for controlling inflammatory 
response, has been shown to play a central role in inflammatory diseases, including kidney 
diseases [33]. In normal rats, only tubular epithelial cells were weakly stained by the 
monoclonal anti-NF–κB antibody, while glomeruli were hardly stained. In control uraemic 
rats, however, proximal tubular epithelial cells, especially of dilated tubules, were 
intensively stained by the anti-NF–κB antibody. In contrast, in the HE-86-treated uraemic 
rats activation of the NF-B in tubular epithelial cells was less prominent as compared with 
that in the control uraemic rats. The staining of NF–κB as shown in the control uraemic rats 
found increased NF–κB -positive (intensively stained) area in the renal cortex, whereas HE-
86-treated rats showed markedly decreased NF–κB -positive area as compared to the control 
uraemic rats. These data demonstrate that HE-86 markedly reduces the overexpress of NF–
κB on the remnant tubular cells.  
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Fig. 1. Immunohistochemistry demonstrates that HE-86 inhibits renal NF－B accumulation 
within the kidney. The accumulation of NF－B in the glomerular and tubulointerstitium is 
markedly increased in empty vector-treated animals (C, D), compared to normal sham-
controls (A,B), which is substantially inhibited in 5/6 nephrectomized rats treated with HE-
86 (E, F). Original magnifications, x100. 
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Fig. 2. Semiquantitative analysis of the therapeutic effect of HE-86 on NF–B localization in 
the glomerulus and tubulointerstitium using the Quantitative Image System. A: Percentage 
of glomerular and tubulointerstitial NF–B deposition in sham group. B: Percentage of NF–
B localization in glomerular and tubulointerstitial without treatment C: Percentage of 
glomerular and tubulointerstitial NF–B accumulation in twelve rats treated with HE-86 
was decreased significantly. Each bar represents data (mean ± SEM) #, P < 0.05 and ##,  
P < 0.001, when compared to empty vector-treated controls; *, P < 0.05 and **, P < 0.01, when 
compared to the normal sham-control. 
10. Effects of HE-86 administration on mRNA levels of TNF–α, Ang II and AT II 
R in renal tissue  
The effects of HE-86 on the gene expression of Ang II (Figure 3), AT1R (Figure 4) and 
TNF– (Figure 5) in the renal cortex were examined. We investigated the potential 
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mechanisms whereby HE-86 suppressed rat tubular interstitial fibrosis and glomerular 
cirrhosis. TNF-, being key proinflammatory cytokines in anti-GBM glomerulonephritis, 
and a group of chemotactic and adhesion molecules including ICAM-1, MCP-1, was 
examined. In vehicle-treated chronic renal failure rats, there was a substantial increase in 
renal mRNA expression of TNF-, Treatment with HE-86 significantly reduced 
upregulation of TNF- inflammatory genes examined (P<0.05). Furthermore, HE-86 was 
capable of attenuating renal cortical mRNAs for Ang II and AT1R as compared with the 
control uraemic rats when they were administered after the establishment of 
nephrectomized. However, the renal mRNA levels of Ang II and AT1R were markedly 
increased in control uraemic rats as compared with normal rats. The variation in the 
mRNA levels of TNF–, Ang II and AT1R in both HE-86-treated and control uraemic rats 
are related to variation in the extent of CRF. 
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Fig. 3. Real-time PCR reveals the inhibitory effect of HE-86 liquid extract on renal Ang II 
mRNA expression(A). and Semiquantitative analysis of the therapeutic effect of HE-86 on 
Ang II mRNA localization in the glomerulus and tubulointerstitium using the FR-2000 
Image Analyze System. A: Degree of glomerular and tubulointerstitial Ang II mRNA 
expression in sham group. B: Numbers of Ang II mRNA expression in glomerular and 
tubulointerstitial without treatment C: Numbers of glomerular and tubulointerstitial cells 
with nuclear localization of Ang II mRNA in twelve rats treated with HE-86 was decreased 
significantly. Each bar represents data (mean ± SEM) ＃, P < 0.05 and ＃＃, P < 0.01, when 
compared to empty vector-treated controls; *, P < 0.05 and **, P < 0.01, when compared to 
the normal sham-control. 
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Fig. 4. Real-time PCR reveals the inhibitory effect of HE-86 liquid extract on renal 
AT1RmRNA expression(B). and Semiquantitative analysis of the therapeutic effect of HE-86 
on AT1RmRNA localization in the glomerulus and tubulointerstitium using the FR-2000 
Image Analyze System. A: Degree of glomerular and tubulointerstitial AT1RmRNA 
expression in sham group. B: Numbers of AT1RmRNA expression in glomerular and 
tubulointerstitial without treatment C：Numbers of glomerular and tubulointerstitial cells 
with nuclear localization of AT1RmRNA in nephrectomized rats treated with HE-86 was 
decreased significantly. Each bar represents data (mean ± SEM) ＃, P < 0.05 and ＃＃, P < 
0.01, when compared to empty vector-treated controls; *, P < 0.05 and **, P < 0.01, when 
compared to the normal sham-control 
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Fig. 5. Real-time PCR reveals the inhibitory effect of HE-86 liquid extract on renal 
TNF－mRNA expression(C). and Semiquantitative analysis of the therapeutic effect of HE-
86 on TNF－mRNA within the glomerulus and tubulointerstitium using the FR-2000 
Image Analyze System. A: Degree of glomerular and tubulointerstitial TNF－mRNA 
expression in sham group. B: Numbers of TNF－mRNA expression in glomerular and 
tubulointerstitial without treatment C: Numbers of glomerular and tubulointerstitial cells 
with nuclear localization of TNF－mRNA in nephrectomized rats treated with HE-86 was 
decreased significantly. Each bar represents data (mean ± SEM) ＃, P < 0.05 and ＃＃, P < 
0.01, when compared to empty vector-treated controls; *, P < 0.05 and **, P < 0.01, when 
compared to the normal sham-control. 
11. Discussion 
Renal fibrosis is a final common pathway to end-stage renal disease. Recent studies have 
shown that hypertensive nephropathy is a major leading cause of end-stage renal disease 
and the renin-angiotensin system plays a pivotal role in the development of progressive 
renal injury [34-35]. Clinical trials have shown that blocking the effects of angiotensin II 
(Ang II) with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers 
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can prevent or slow the progression of kidney damage in patients with diabetes and 
hypertension [34-36].  
As expected, 5/6 renal ablation promoted growth retardation, systemic arterial 
hypertension, impaired renal function, and severe albuminuria. These functional changes 
were accompanied by severe glomerulosclerosis, as well as expansion and intense 
macrophage infiltration of the interstitial area. Mounting evidence indicates that these 
renal structural abnormalities, which are characteristic of the Nx and other models of 
progressive nephropathies, are a consequence of the concerted action of mechanical stress, 
caused by glomerular hypertension and hypertrophy [37-38], and inflammatory 
phenomena, comprising cell infiltration and/or proliferation and extracellular matrix 
accumulation [38-39]. Moreover, a causal relationship appears to exist between these 
phenomena, because the distension of the glomerular walls due to intracapillary 
hypertension may trigger the local release of cytokines, growth factors, and, particularly, 
Ang II and AT-1 receptors [40-41]. 
The beneficial effect of RAS suppressors was initially attributed to amelioration of the 
glomerular hemodynamic dysfunction associated with progressive nephropathies. 
However, recent observations suggest that the nonhemodynamic effects of RAS suppressors 
may be equally important, given the strong proinflammatory and profibrotic effects of Ang 
II [42]. A substantial fraction of this proinflammatory ANG II may originate in the renal 
parenchyma, rather than in renal vessels or in the systemic circulation [43]. Increased 
intrarenal production of ANG II was described in various models of renal fibrosis [44-46]. A 
preliminary report has suggested that, in the 5/6 renal ablation (Nx) model, ANG II is 
expressed in renal interstitial cells, paralleling the severity of renal injury [47].  
Increasing evidence shows that angiotensin II (Ang II) plays a critical role in cardiovascular 
disease and is a key mediator in the process of vascular fibrosis, characterized by reduced 
lumen diameter and arterial wall thickening attributable to excessive deposition of 
extracellular matrix (ECM). Vascular fibrosis is a major complication of hypertension and 
diabetic mellitus. It has been shown that upregulated tissue rennin-angiotensin system is 
involved in development of vascular lesions in both human and experimental vascular 
diseases [48-49]. This observation is confirmed by the finding that infusion of Ang II is able 
to induce vascular fibrosis in rats [50]. The functional importance of Ang II in vascular 
fibrosis is further supported by the evidence that blockade of Ang II inhibits vascular 
fibrosis in diabetic and subtotal nephrectomy rats and NO-deficient mice [51-53].  
Both the hemodynamic and proinflammatory effects of Ang II are mediated by AT-1 
receptors (AT1R) [54], extensively expressed in renal tissue. In the normal rat kidney, AT1R 
are predominantly expressed in tubular cells and vessels [55]. Recent data obtained with the 
Nx model have suggested that AT1R expression is shifted from the glomerular to the 
tubulointerstitial compartment 4 wk after ablation [56]. However, the renal distribution of 
AT1R in this model and its temporal evolution have not been established. 
Beyond its hemodynamic effects, Ang II is recognized as a cytokine with an active role in 
cardiovascular remodeling. It is well known that Ang II signals through its Ang II receptor 1 
(AT1) receptor to exert most of its biological functions [57]. After binding to the AT1 
receptor, Ang II activates multiple downstream intracellular signaling pathways, including 
tyrosine kinase, mitogen-activated protein kinase (MAPK), p38, and Janus family kinase 
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[58]. Activation of these pathways leads to numerous heterogeneous downstream events 
that play essential roles in the biological activities of Ang II, such as cell growth and 
migration, ECM production, and apoptosis [58]. 
Renal expression of AT1R in rats appeared mostly in tubular cells, and to a lesser extent, at 
the interstitial area, whereas weaker expression was seen in vessels and glomeruli. This 
pattern was completely disrupted after Nx, when dense AT1R expression could be 
demonstrated in interstitial cells, far exceeding in intensity the expression of AT1R in 
tubules. The exact meaning of this finding and the cell types involved are uncertain. Several 
inflammatory cells known to infiltrate the renal interstitium in the Nx model have the 
potential to express AT1R, such as lymphocytes [59] and macrophages [60]. In addition, 
AT1R may be expressed by myofibroblasts originating from tubular cell transdifferentiation 
[61]. This hypothesis is particularly attractive because it helps to explain the progressive 
shift in AT1R expression, from tubules to the interstitial area, observed in Nx rats, and also 
because tubular cells already express AT1R under normal conditions. The simultaneous 
presence at the interstitial area of large amounts of Ang II and of the AT1R may accelerate 
the progression of the nephropathy by a positive-feedback mechanism. Consistent with this 
view is the aggravation of the renal structural injury of Nx, which was paralleled by the 
intensity of the inflammatory infiltration and of the interstitial expression of Ang II. 
It is well accepted that NF-B is a key transcriptional factor to regulate a variety of 
inflammatory responses [75]. NF-B is composed of p50 and p65 subunits, among which 
p65 is a potent transcriptional activator, strongly promoting inflammatory reaction in 
kidney diseases [76]. NFB total protein expression, and inflammation, which may have 
resulted from blockade of the oxidative stress pathway [77-78]. This was accompanied by a 
substantial attenuation in renal fibrosis, which might have resulted from the modulating 
actions of vitamins on lipid peroxidation and profibrotic activity involved in renal tissue 
damage [79-82]. In this study, marked activation of NF-B was closely correlated with the 
renal inflammation. In our study, using liquid extract isolated from clinical effective Chinese 
prescription, we were able to show that overexpression activation of NF-B was 
substantially suppressed as compared with control group. These findings are consistent 
with the improving renal function and correcting high blood pressure. 
Tumour necrosis fator-ǂ(TNF-ǂ)is a potent pro-inflammatory cytokine which is produced 
by many cell types including monocytes/macrophages, and renal mesangial and epithelial 
cells. It induces the expression of major histocompatibility complex (MHC) class I and II 
molecules, endothelial adhesion molecules and procoagulant activity of endothelium. TNF-
ǂ stimulates the release of other pro-inflammatory cytokines, chemokines and growth 
factors, including interleukin-1ǃ(IL-1ǃ), monocyte chemoattractant protein-1 (MCP-1) and 
transforming growth factor-ǃ(TFG-ǃ) [83-84]. The biological effects of TNF-ǂ are mediated 
by binding to specific receptors which are widely distributed. TNF-ǂ binds to two types of 
receptor: TNF receptor type 1 and TNF receptor type 2, which have molecular weights of 55 
kDa (p55) and 75 kDa (p75), respectively. Both receptors are necessary and act 
synergistically for cell proliferation and maturation, cytotoxicity and antiviral activity, but 
p55 is responsible for activation of NFкB and mediation of apoptosis [85].  
TNF- may contribute to renal damage by inciting an inflammatory response within the 
kidney via induction of a variety of chemokines and adhesion molecules [86-87]. There is a 
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mounting evidence to implicate TNF-ǂ in the pathogenesis of glomeruli of rodents with 
experimental nephritis, and is found in renal biopsies, sera and urine of patients with 
different types of glomerulonephritis [88-91]; In vitro and in vivo studies document that 
TNF-ǂ is produced locally within inflamed glomeruli by mesangial and epithelial cells, as 
well as by infiltrating monocytes/macrophages [89,91]; Systemic administration of TNF-ǂ 
results in glomerular damage in rabbits [92] and exacerbates the degree of glomerular injury 
in nephrotoxic nephritis in rats [93]; and blocking endogenous TNF-ǂ in nephrotoxic 
nephritis in rats ameliorates acute glomerular inflammation [94], and down-regulates 
glomerular IL-1ǃmRNA and circulating TNF-ǂ concentrations [95]. 
Treatment of Nx rats with the HE-86 promoted a significant regression of hypertension, 
high level of creatinine and blood urea nitrogen, albuminuria, and inflammatory signs such 
as urine TGF-ß and renal tissue TNF-ǂ, NF-B, Ang II and AT1R expression, whereas the 
parameters of renal structural tissue injury were strongly attenuated, compared with 
pretreatment levels. The protection achieved with effective unit from clinical prescription 
treatment was much greater than that obtained with traditional prescription alone. On the 
basis of the present study, we cannot exclude the hypothesis that the success of HE-86 was 
due to a particularly effective hemodynamic action, although previous observations from 
this laboratory [96] indicated that NOF, a new nonsteroidal anti-inflammatory, had no 
significant effect on glomerular hemodynamics. Because treatment with NOF alone had no 
effect on blood pressure, it seems unlikely that the hemodynamic effect of NOS was directly 
intensified by its association with NOF. Therefore, the efficacy of extract HE-86 was likely 
due to the simultaneous blockade of the hemodynamic and proinflammatory actions of Ang 
II, AT1R and its derivatives as TNF-, NF-B, TGF-ß and by abrogation of the complex 
interplay between hypertension and inflammation. The present findings support other 
scholars’ observations of the Nx model, which similarly indicated the superiority of the 
combination of a RAS suppressor with an anti-inflammatory agent [97-99]. It is noteworthy 
that HE-86 afforded partial regression of the nephropathy associated with Nx even though it 
was started 4 week after surgery, when renal injury was already established. This 
observation suggests that both continued stimulation of Ang II and AT1 receptors and 
production of inflammatory factors continue to play an important pathogenic role even 
during the late phases of the process, necessitating vigorous and persistent treatment to 
prevent further renal deterioration. 
Taken together with our previous data and the present results, it is likely that HE-86-
induced reduction of renal rennin-angentensin system is mediated, at least partly, by 
reducing the overload of inflammatory factors activity on remnant kidney unit. In summary, 
HE-86effective composition coming from clinical validly treating patients with chronic renal 
failure especially for early and middle stage, partially reversed the nephropathy and renal 
inflammation associated with the Nx model, showing much more effective protection than 
with traditional Chinese medicine prescription.  
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